Advertisement

Virchows Archiv

, Volume 456, Issue 2, pp 181–192 | Cite as

Running GAGs: myxoid matrix in tumor pathology revisited

What’s in it for the pathologist?
  • Stefan M. Willems
  • Malgorzata Wiweger
  • J. Frans Graadt van Roggen
  • Pancras C. W. Hogendoorn
Open Access
Review and Perspective

Abstract

Ever since Virchow introduced the entity myxoma, abundant myxoid extracellular matrix (ECM) has been recognized in various reactive and neoplastic lesions. Nowadays, the term “myxoid” is commonly used in daily pathological practice. But what do today’s pathologists mean by it, and what does the myxoid ECM tell the pathologist? What is known about the exact composition and function of the myxoid ECM 150 years after Virchow? Here, we give an overview of the composition and constituents of the myxoid ECM as known so far and demonstrate the heterogeneity of the myxoid ECM among different tumors. We discuss the possible role of the predominant constituents of the myxoid ECM and attempt to relate them to differences in clinical behavior. Finally, we will speculate on the potential relevance of this knowledge in daily pathological practice.

Keywords

Extracellular matrix Glycosaminoglycans Proteoglycan Collagen Myxofibrosarcoma Intramuscular myxoma 

Historical perspective

In his 1858 masterpiece Cellularpathologie, Rudolph Virchow introduced the term “myxoma” to describe a soft tissue tumor, histologically resembling the structure of the umbilical cord (Figs. 1 and 2) [1]. This description of myxoma was adopted in the seventh edition of the Medical Lexicon by Robley Dunglison who remarkably added that “[myxoma] was for the first time described in 1838 by Johannes Müller as Collonema” [2]. Müller used the term collonema (κολλα = glue) for “peculiar gelatinous tumours, consisting of a remarkably soft gelatiniform tissue, which trembles on being touched” [3]. Though this description is applicable to most myxoid tumors, it holds also for many nonmyxoid tumors and it is not particularly clear which tumor type Müller had in mind. Today, it has been generally accepted that it was indeed Virchow who introduced myxoma as an entity. The introduction of this new histological concept of tumors containing myxoid (μύξα = “mucus” and ειδος = “resemblance”) areas soon led to the recognition of new entities, such as myxadenoma, myxochondroma, myxofibroma, and myxoneuroma [2]. The term myxosarcoma, introduced in 1802 by Bryant [4], became reserved for malignant tumors and defined as “a mucous transformation of round-celled sarcoma, malignant, and of large volume, usually attacking the omentum and the skin” [2]. Nowadays, myxoid changes/areas are recognized in both benign and malignant neoplasms (primarily classified as mesenchymal or epithelial) as well as non-neoplastic (reactive) lesions (Fig. 3).
Fig. 1

Timetable with key events in studies on myxoid tumors of soft tissue. Though Müller already mentioned tumors with a macroscopically gelatinous appearance in 1838 [3], it was in 1858 when Virchow introduced the term myxoma to describe tumors which morphologically resembled the jelly structure of the umbilical cord [1]. Ever since, the term myxosarcoma, introduced by Bryant in 1802 was reserved for the malignant counterparts [4]. Because of their morphologically overlapping features, both terms were used interchangeably, which was mentioned by Stout in 1948 as unwise, warranting for macroscopical and microscopical criteria for the reliable differential diagnosis between the two entities [5]. The relationship between myxomas and fibrous dysplasia was first described in 1926 by Henschen [90], though it was Mazabraud who proposed it as a syndrome in 1967 [91]. The association of cardiac/cutaneous myxomas, hyperpigmentation of the skin, and endocrine overactivity was only recognized in 1985 by Carney [43]. Progress in the study of the myxoid ECM was made by the invention of the alcian blue staining in 1950 by Steedman [9], and Scott who developed the CEC method to distinguish the different GAGs in 1965 [10]. Based upon this technique, Kindblom showed in 1975 that different bone and soft tissue tumors (including myxoid ones) contained different GAGs [11]. From the late 1980s, it became clear that the ECM is a key player in tumor development and tumor progression, sustained by an exponentially growing number of publications [40]. As myxoid areas were now being recognized as an intrinsic part of a subset of tumors, Weiss and Angervall simultaneously described the myxoid variant of malignant fibrous histiocytoma/myxofibrosarcoma as a distinct entity [92, 93]. Parallel to morphological classification, an increasing number of myxoid tumors showed specific molecular genetics aberrations, such as (activating) mutations and translocations. The concept of malignant progression in myxoid tumors of soft tissue (i.e., myxoid liposarcoma) due to chromosomal instability and subsequent secondary genetic events was described in 1990 by Orndal et al. [94]. Nowadays, classification of myxoid tumors of soft tissues is based upon clinicopathological and molecular/cytogenetic aberrations as published in the 2002 WHO classification [7]

Fig. 2

Characteristic macroscopy and histomorphology of the myxoid ECM. Rudolph Virchow introduced the term myxoma for those tumors morphologically resembling Wharton’s jelly of the umbilical cord (a), which contains large amounts of GAGs as detected by alcian blue (b). High-power image of Wharton’s jelly showing abundant myxoid ECM containing fibrillary collagens, interspersed between myofibroblast-like stroma cells (c). Intramuscular myxoma characteristically has a gelatinous appearance on cut surface (d) and is well circumscribed towards its peripheral tissue (e). On higher magnification, it shows the same abundant myxoid ECM as the umbilical cord (c) and no significant atypia of the sparse tumor cells (f). Histological criteria are still a hallmark of diagnosis, showing characteristic lobulated, hypocellular morphology of grade I myxofibrosarcoma at low magnification (g).Curvilinear blood vessels are often seen in grade I myxofibrosarcoma (but are not diagnostic), whereas tumor cells show vesicular, slightly atypical nuclei compared to intramuscular myxoma (h). Another hallmark of myxofibrosarcoma is areas with abrupt transition of grade (i) which was already mentioned by Mentzel et al. [95]

Fig. 3

Myxoid ECM is a ubiquitously histological feature in physiological and pathological conditions. Myxoid ECM is a morphological feature in physiological and pathological conditions, such as in myxedema due to increased production of HA. Myxoid areas/changes are also commonly present in tumors (both of epithelial and mesenchymal origin). In epithelial tumors, myxoid changes are often a secondary phenomenon, whereas in mesenchymal tumors, they are more frequently an intrinsic part of the tumor entity. This group of so-called myxoid tumors of soft tissues contains an increasing number of entities (e.g., myxofibrosarcoma, formerly called myxoid variant of malignant fibrous histiocytoma), sometimes sustained by specific distinct molecular/cytogenetic aberrations (e.g., myxoid liposarcoma)

In his first description, Virchow had already recognized the recurrent nature of some myxomatous tumors [1] and it became clear that it was difficult to predict the exact clinical behavior of these different tumors based on their myxoid morphology alone. Subsequently, the terms myxoma and myxosarcoma were used interchangeably till Arthur Stout recognized this as unwise [5] because “myxomas do not metastasize and there is no way to anticipate differences in their growth energy from their histopathology.” Later studies confirmed the distinction between both entities on the basis of macroscopical and microscopical features (necrosis, nuclear atypia, and mitotic figures; Fig. 2) [6]. Today, myxoid tumors of soft tissue are classified according to the World Health Organization (WHO) formulation based on clinicopathological criteria and specific molecular/cytogenetic aberrations (Table 1) [7, 8]. So what is left of the term “myxoid” 150 years after Virchow? What do today’s pathologists mean by it, and what does the myxoid extracellular matrix (ECM) tell the pathologist? What is the exact composition of this myxoid ECM and does it have a function? Here, we give an overview of the composition and constituents of the myxoid ECM as known so far and demonstrate the heterogeneity of the myxoid ECM among different tumors. We discuss the possible role of the predominant constituents of the myxoid ECM and attempt to relate them to differences in clinical behavior. Finally, we will speculate on the potential relevance of this knowledge in daily pathological practice.
Table 1

Myxoid tumors of soft tissue: overview of clinicopathological and genetic features

Myxoid tumors of soft tissue

Age

Sex

Predilection site

Molecular/cytogenetic aberrations

References

Benign

Intramuscular myxoma (including its cellular variant)

Adults

F>M

Thigh, shoulder, buttocks, and rarely upper arm

GNAS1 mutations

[34]

Myxoid neurothekeoma

Young adults

F>M

Head, neck, and shoulders

Loss of 22q

[8]

Myxoid lipoma (myxolipoma)

Any age

F=M

Head and neck

Rearrangement of 13q and/or 16q

[8]

Myxoid chondroma

Adults

M>F

Hands and feet

Extra copies of chromosome 5 or 12q13–15 rearrangement

[8]

Myxoid neurofibroma

Any age

M=F

All over the body

NF1 mutations

[8]

Myxoid dermatofibroma

Young adults

F>M

Lower extremities

Unknown

[42]

Cardiac myxoma

Adults

F>M

Atria (predominantly left)

PRKAR1α mutations in Carney complex

[43]

Ossifying fibromyxoid tumor

Elderly

M>F

Extremities and trunk

Nonspecific cytogenetic aberrations

[8]

Cutaneous myxoid cyst

Any age

F>M

Distal and dorsal portions of fingers (and toes)

Unknown

[8]

Cutaneous myxoma (superficial angiomyxoma)

Adults

M>F

Trunk, lower extremities, head, and neck

PRKAR1α mutations in Carney complex

[43]

Myxoid nodular fasciitis

Young adults

M=F

Head, neck, and extremities

Nonspecific cytogenetic aberrations

[8, 44]

Locally aggressive

Odontogenic myxoma

Young adults

F>M

Mandible and maxilla

PRKAR1α mutations in rare cases (not Carney complex)

[45]

Myxoinflammatory fibroblastic sarcoma

Adults

M=F

Feet, lower leg

t(1;10)(p22;q24) and amplification of chromosome 3

[46]

Aggressive angiomyxoma

Adults

F>>M

Inguinal region

Rearrangement of 12q13-15

[8]

Malignant

Myxofibrosarcoma

Elderly

M=F

Extremities, thigh

Nonspecific cytogenetic aberrations

[47, 48]

Extraskeletal myxoid chondrosarcoma

Adults

M>F

Extremities and limb

t(9;22)(q22;q12), t(9;17)(q22;q11) or t(9;15)(q22;q21)

[49]

Low-grade fibromyxoid sarcoma

Young adults

M>F

Proximal extremities and trunk

t(7,16) (q33;p11)

[50]

Myxoid liposarcoma

Elderly

M>F

Lower extremities and thigh

t(12;16)(q13;p11) or t(12;22)(q13;q12)

[51]

Myxoid leiomyosarcoma of soft tissue

Adults

F>>M

Limbs, female genitalia, head, and neck

Nonspecific cytogenetic aberrations

[52]

Myxoid malignant peripheral nerve sheath tumor

Adults

F=M

Extremities, trunk

NF1 and TP53 mutations, P16 deletions

[8, 53]

Myxoid dermatofibrosarcoma

Adults

M=F

Trunk, groin, and extremities

t(17;22)(q22;q13)

[54]

Composition of the myxoid extracellular matrix

Glycosaminoglycans and proteoglycans

Substantial progress in the study of the myxoid ECM was made after the introduction of alcian blue staining in 1950 [9]. John Scott was one of the pioneers who used this histochemical stain to distinguish between the different glycosaminoglycans (GAGs) in tissue sections [10]. Kindblom et al. showed that the myxoid ECM of various (non)neoplastic tissues, i.e., Wharton’s jelly and myxoid tumors of soft tissue, contained large amounts of GAGs (Figs. 1 and 2) [11]. GAGs are large macromolecules abundantly present in pericellular and extracellular matrices and consist of unbranched polysaccharide chains of disaccharides which are often sulfated. There are six different types of GAGs: hyaluronic acid (HA), keratin sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin [12]. GAGs form proteoglycans (PGs) once covalently attached to specific core proteins. Core proteins of PGs are synthesized in the endoplasmic reticulum and post-translationally modified as they pass through the Golgi apparatus where hexuronic acid and hexosamine groups are attached. The exception is HA, which is synthesized directly under the cytoplasmic membrane by the hyaluronic acid synthetases 1, 2, and 3 [12]. The most common classification of the different PGs is based upon the properties of the core protein. The three main PG families present in the ECM are lecticans, small leucine-rich proteoglycans (SLRPs), and other ECM PG [13]. Lecticans always contain both a hyaluronan-binding domain and a C-type lectin domain. The lectican family includes: aggrecan, versican, neurocan, and brevican that can be found at different locations (Table 3) [12]. SLRPs can be found extracellularly and intracellularly and at the cell surface. They contain nine to 12 tandem repeats of leucine-rich motifs which involve their collagen-binding domains. The SLRP family includes decorin, biglycan, asporin, ECM protein 2, keratocan, proline/arginine-rich and leucine-rich repeat proteins, osteoadherin, lumican, fibromodulin, opticin, epiphycan, osteoglycin, podocan, chondroadherin, and nyctalopin [14]. ECM PGs do not show significant homology in the content of their core proteins. Perlecan, agrin, and collagen types XV and XVIII belong in this family [14]. Various GAGs and PGs have been identified in the myxoid ECM (Table 2): HA is the most common; none of them are specific for one particular lesion.
Table 2

The composition of the myxoid ECM is heterogeneous but not lesion-specific

Proteoglycans

Collagens (types)

Other ECM components

References

Non-neoplastic myxoid lesions

Follicular mucinosis

HA

  

[55]

Myxedema

HA

I (III)

 

[56, 57]

Stenotic arteries

Versican, biglycan, perlecan, HA

I

TBFbeta1

[58, 59]

Pseudoaneurysm

Versican

  

[60]

Endocardiosis

HA

  

[61]

Valvular degeneration of the heart

 

I, III

 

[62]

Myxoid tumors of soft tissue

Intramuscular myxoma

KS, HA, C4S, C6S

I, VI

Albumin, IgGs

[20, 34]

Myxofibrosarcoma

KS, HA, C4S, C6S

I, VI, XII, XIV

Thrombospondin Albumin, IgGs

[8, 20, 34]

Extraskeletal myxoid chondrosarcoma

C4S, C6S, HA (aggrecan)

I, III, VI (II, IV)

Albumin, IgGs

[20, 63]

Odontogenic myxoma

C4S, C6S, DS, KS, HS, aggrecan, versican, biglycan, decorin

  

[64]

Low-grade fibromyxoid sarcoma

HA

  

[65]

Myxoid neurothekeoma

HA

  

[66]

Myxoid lipoma (myxolipoma)

HA

  

[67]

Myxoid liposarcoma

HA

 

FN

[68]

Myxoid chondroma

HA, KS

  

[69]

Myxoid neurofibroma

HA, C4S, C6S

  

[69]

Chondromyxoid fibroma

Aggrecan

I, III, VI

 

[70]

Myxoid dermatofibroma

HA

  

[71]

Myxoid leiomyosarcoma

HA

  

[72]

Cardiac myxoma

C4S, C6S, (HA)

  

[73]

Ossifying fibromyxoid tumor

 

IV (II)

 

[74, 75]

Myxoinflammatory fibroblastic sarcoma

  

A1AT, A1ACT

[76]

Cutaneous myxoid cyst

HA

  

[77]

Aggressive angiomyxoma

HA

  

[78]

Cutaneous myxoma (superficial angiomyxoma)

HA

  

[79]

Myxoid areas in epithelial tumors

Breast carcinoma

Aggrecan, versican, HA

I, II, IV

 

[80]

Pleiomorphic adenoma

Lumican, perlecan, aggrecan, C4S, C6S, DS, KS, HA

I, III, IV

FGF2, Tenascin, FN, ChM-I

[81, 82, 83]

Vulvar squamous cell carcinoma

  

CD44, TGF-beta3

[84]

Mixed tumor of skin

 

IV

Tenascin, FN

[85]

Cholangiocarcinoma

Perlecan

  

[86]

Miscellaneous tumors (nonsoft tissue, nonepithelial)

Myxopapillary ependymoma

HA, CS, HS

  

[87]

Myxoid mesothelioma

HA

  

[88]

Myxoid meningioma

HA, CS

  

[89]

KS keratin sulfate, HA hyaluronic acid, C4S chondroitin sulfate, C6S chondroitin 6 sulfate, DS dermatan sulfate, HS heparan sulfate

Collagens

One of the first papers addressing myxoma and its malignant counterpart (“myxosarcoma”) mentioned the presence of fibrillary collagens as a hallmark for differential diagnosis [6]. Though this criterion did not last long, collagens (κολλα = glue; γηνε = that which produces) are a main component of the myxoid ECM. They are characterized by their regular, triple-stranded helix of so-called alpha-chains forming cord-like strands of 300 nm in length and 1.5 nm in diameter. A separate group of collagens is formed by the fibril-associated collagens with interrupted triple helices (FACIT) and includes collagen types XII and XIV. These collagens have several triple helical domains (collagen type domains [Col]) separated by nontriple helical domains (NC). All collagens contain large amounts of proline and glycine as well as hydroxyproline and hydroxylysine which are formed by post-translational modification. Based on their biochemical differences, more than 30 different types of collagens are recognized [15]. The most common types are I, II, III, and IV, which account for 90% of all collagens in humans. Except for collagen II, which is predominantly present in cartilage, collagen types I, III, and IV as well as VI, XII, and XIV may be found in the myxoid ECM (Table 2).

Other ECM molecules

Other structural molecules identified in the myxoid ECM are fibronectin and tenascin C (Table 2). Fibronectin is a fibril-forming glycoprotein existing in a dimeric or multimeric form. Each monomer contains several binding sites for fibrin, heparin, DNA, and cells. Fibronectin molecules consist of different repeats (types I, II, and III) and three different sites that can be alternatively spliced (EDA, EDB, and V). The dimeric, soluble form is produced by hepatocytes and lacks the alternative EDA and EDB variants. The multimeric form is extensively present in granulation tissue, basement membrane, and on cell surfaces and contains variable proportions of the EDA and EDB domains [16]. Until now, fibronectin has only been found in myxoid liposarcoma but might also be present in the ECM of other myxoid lesions (Table 2).

Tenascin C is a highly conserved glycoprotein of the ECM consisting of 300 kDa monomers, characteristically assembled in 1,800 kDa hexamers [17, 18]. It consists of several functionally independent domains of which the number is dramatically increased by alternative splicing. The N-terminal contains the cysteine-rich assembly domain, followed by EGF-like repeats, eight constant and up to nine alternatively spliced fibronectin type III repeats and a C-terminal fibrinogen-like globular domain [18]. Till today, its presence has only been shown in myxoid areas of epithelial but not (yet) in mesenchymal tumors (Table 2).

Functional role of the different constituents in the myxoid extracellular matrix

Glycosaminoglycans

GAGs have both biophysical and biochemical functions and play important roles in physiologic and neoplastic processes (Table 3) [19]. Due to their high content of sulfate and carboxyl groups, complex patterns of sulfation and uronic acid epimerizations, GAG chains confer upon PGs the diverse capacities to function as ideal physiological barriers, reservoirs for signaling proteins, and binding partners for structural macromolecules [13]. We have shown that the myxoid ECM in soft tissue tumors is heterogeneous in composition and that the relative amount of each GAG is tumor-type- and tumor-grade-dependent [20]. Because of their negative charge, all GAGs, especially HA, are able to trap water molecules. Interestingly, HA is the common denominator in the myxoid ECM (Table 2). This suggests that HA is the major contributor to the edematous appearance of the myxoid ECM. As a result of the biophysical properties of GAGs (their high viscosity and low compressibility), they are ideal for tissue lubrication. On the other hand, their rigidity is responsible for the structural integrity of tissues facilitating diffusion of metabolites and cell migration [21]. The biochemical properties of GAGs are mediated by specific binding to other macromolecules. GAGs can bind to secreted proteases and antiproteases, growth factors, structural ECM proteins, and proteins expressed on (tumor) cells [22]. Chondroitin sulfate modulates cell fate as it appears to prevent apoptosis and is involved in cell proliferation. Since chondroitin sulfate is much more abundant in the ECM of extraskeletal myxoid chondrosarcoma compared to intramuscular myxoma and myxofibrosarcoma, it might, therefore, play a role in the more malignant behavior of this tumor [20]. Large multidomain ECM molecules such as collagen types I, III, V, and XIV and fibronectin contain at least one GAG binding site. This allows them to bind to heparan and chondroitin sulfates on cells or in the ECM, contributing to proper ECM formation.
Table 3

GAGs and PGs: their role in physiology and pathologic processes [19]

Type and presence

Physiology

Pathology

C4S (CS-A)

Sulfated galactosaminoglycan; cartilage, skin and tendon

Binds Ca2+, Cu2+ and Fe2+ ions; antioxidant (better then C6S and HA)

Decreased in OA, mediate adherence of plasmodium infected red blood cells

C6S (CS-C)

Sulfated galactosaminoglycan; cartilage, brain secretory granules

Reduces proinflammatory cytokines, MMPs, NO, and apoptosis

Laryngeal cancer, decreased in OA, increased in early atherosclerotic lesions

DS (CS-B)

Sulfated galactosaminoglycan; skin, blood vessels, heart, tendons, lungs

Regulation ECM integrity and cellular signaling; DS selectively activates heparin cofactor II that inactivates thrombin; carcinogenesis, wound repair, and fibrosis; DS binds water, coagulation

Dermatan sulfate accumulates abnormally in several of the mucopolysaccharidosis disorders and in myxomatous degeneration. Involved in cardiovascular disease, infection, fibrosis

HA

Lack sulfation and epimerization of glucuronic acid moiety to uronic acid, the only GAG synthesized in the cytoplasm at the plasma membrane and also the only GAG that is synthesized without core protein. Connective, epithelial and neural tissue. abundant in cartilage and bone

Early development, tissue organization, cell proliferation, facilitate migration and condensation of mesenchymal cells, participates in joint cavity formation, binds and immobilizes aggrecan, regulates osteoblast and osteoclast function. HA works as a scaffold for building PGs, suppresses cartilage degeneration and reduce pain perception, associated with cell adhesion and motility, suppresses prostaglandin E2 and IL-1 production, activates SRC, FAK, ERK and PKC whereas interaction with CD44 also regulates ERBB, PI3K, regulates phosphorylation of BAD and hence promotes cell survival, contributes to cell proliferation and migration, bone turnover, involved in tissue repair in skin, binds to receptor CD44

Used for treatment of osteoarthritis

HS

Sulfated glucosaminoglycan; all types of cells, highly abundant in ECM of the skeleton

Coreceptors for morphogens, sequester growth factors and cytokines to regulate cell differentiation and growth, compose ECM scaffolds that make physical separation of the niche from cellular and signaling influence of surrounding environment, involved in skeletal patterning, differentiation, growth and homeostasis, critical for hematopoietic stem cell inch, Ndst1 mutation causes brain/skull defects and lung surfactant problems resulting in perinatal lethality, Ndst2 mutant have defective granule formation in mast cells, stimulates angiogenesis, osteocastogenesis, skeletal patterning, differentiation and homeostasis, coreceptor for morphogens, sequester growth factors and cytokines to regulate cell differentiation and growth, FGF-binding, binds fibronectin

Sequesters chemokines or FGF towards migrating tumor cells, promotes metastasis, multiple osteochondromas (MO)—benign bone cartilaginous tumor caused by mutant in EXT1 or EXT2, accumulated in mucopolysaccharidoses

KS

Sulfated glucosaminoglycan; N-glycan KSI or O-glycan KSII. Highly abundant in cornea and cartilage. Also found in epithelial tissue, central nervous system

Maintains proper special organization of the type I collagen fibrils and promotes transparency of cornea, cellular recognition of protein ligands, cell motility

Corneal opacity and corneal dystrophy (KS lacks GlcNAc sulfation), epithelial-derived carcinoma cells, alerted sulfation levels of KS was found in brain of Alzheimer patients

Aggrecan

O- and N-linked KSII, CS, DS, KS (HS absent), cartilage

Maintains tissue hydration, contributes to the mechanical properties of tissue, inhibits migration of neural crest cells, null mice show cartilage defects and delay in bone development

Chondrodystrophy, nanomelia, cartilage matrix deficiency (CMD), murine brachymorphism (bm), spondyloepimetaphyseal dysplasia enhanced expression in chondroblastoma, chondroma, chondrosarcoma, osteosarcoma, decreased in squamous cell carcinoma chondrodystrophy, nanomelia, cartilage matrix deficiency, spondyloepimataphyseal dysplasia

Biglycan

CS, DS (HS absent), bone, cartilage, skin, connective tissue

Activates cell division, organization of collage fibers, increased in vascular injury, upregulates p27 and downregulates cyclin A and proliferating cell nuclear antigen, maintaining proper number of mature osteoblasts and survival of bone marrow stromal cells, organization of collagen fibers, regulator of cell cycle, binds TGF-beta

Overexpressed in pancreatic cancer and hyperplasic thymus osteoporosis

Decorin

CS, DS (HS absent), connective tissue, cornea

Inhibits collagen fiber formation by interaction with col I, col II, and col VI, inhibits cell division, adhesion, increased in vascular injury, downregulates Erbb2 and MAP kinases, upregulates p21 CDK inhibitor leading to inhibition of cell proliferation and specific induction of apoptosis in transformed cells. maintaining proper number of mature osteoblasts and maintaining survival of bone marrow stromal cells, bind nonfibril collagens XII and XIV, regulates cell proliferation, binds TGF-beta, mediates EGF signaling by binding to EGFR

Antiproliferative properties in tumor growth, overexpressed in colorectal carcinoma, colon adenocarcinoma, melanoma, osteosarcoma, basal cell carcinoma, inhibits migration of MG-63 osteosarcoma cells, reduced decorin levels were found in lung adenocarcinoma, squamous carcinoma, breast carcinoma, hepatocellular carcinoma and ovarian tumors, may regulate tumor angiogenesis, overexpression is often associated with shift from DS to CS, osteoporosis

Lumican

KS, cornea

Upregulates p27 and downregulates cyclin A and proliferating cell nuclear antigen, regulates collagen fibril organization and circumferential growth, corneal transparency, and epithelial cell migration and tissue repair

Upregulated in pancreatic, colorectal and breast cancers, stroma of salivary pleiotropic adenoma, reduced expression is correlated with progression of breast carcinoma

Perlecan

HS, CS, cartilage, limb bud mesenchyme, articular cartilage, bone marrow stroma, all basal membranes, vasculature

Growth factor signaling, collagen fibrillogenesis, structural stability, vasculogenesis, endorepellin, antiangiogenic factor, chondrocyte proliferation and differentiation, collagen I and II fibrillogenesis, vasculogenesis, mediator of Shh signaling, Wnt signaling, TGF-beta signaling in the skeleton, regulates FGF2 signaling

Schwartz–Jampel syndrome, dyssegmental dysplasia Silverman–Handmaker type (DDSH), perlecan-null embryo chondroplasia, prostate tumor metastasis

Versican

C6S>C4S>DS (HS, KS absent), connective tissue, aorta, brain; fibroblasts. important for vascular biology

Lipid retention, modification and accumulation, hydration of ECM, cell proliferation, migration, embryo development, binds HA, CD44, and chemokines

Promotes tumor growth and spread, expressed in the stroma of nearly all human cancers (prostate, breast, lung, ovarian cancers and odontogenic tumors, melanoma, brain tumors, pharyngeal squamous cell carcinoma, keratinocyte tumors, atherosclerosis)

Proteoglycans

PGs exhibit a wide variety of functions due to their structural diversity (Table 3). As PGs avidly bind proteins, they are involved in all cellular processes concerning cell–matrix, cell–cell, and ligand–receptor interactions. PGs are known to have affinity for a variety of ligands, including growth factors, cell adhesion molecules, ECM components, enzymes, and enzyme inhibitors [22]. Lecticans bind other ECM proteins with its C-type lectin motif, facilitating the formation of networks permissive for cell growth [23]. For example, aggrecan and versican associate tightly with both HA, thereby maintaining tissue hydration. Due to the EGF-like repeats, lecticans are directly involved in growth control. Versican stimulates the proliferation of fibroblasts and is highly expressed by fast-growing cells and present in myxoid areas of both reactive and neoplastic (mesenchymal and epithelial) lesions (Table 2) [24].

Small leucine-rich proteoglycans

SLRPs are structurally and functionally related ECM molecules and abundantly expressed in connective tissues. Decorin and biglycan bind to collagen and influence collagen fibrillogenesis and ECM assembly in various ways: (a) due to its curved shape, decorin is able to bind to collagen types I, II, VI, and XIV linking them together and to fibronectin [25], (b) by decorating collagen fibers, decorin protects them from degradation by collagenases [25, 26], and (c) by its attached GAG chain, decorin is capable of modulating the activity of TGF-beta, which plays a central role in fibrogenesis [13, 25, 27]. Biglycan- and decorin-deficient mice show irregular and defective collagen fibrils, fragile skin, and a phenotype that closely resembles that of patients with Ehlers–Danlos syndrome [28]. In wound healing, there is a spatial temporal regulation of the expression of the different SLRPs (decorin, lumican, fibromodulin, and biglycan) tightly controlling the transformation of the myxoid ECM of granulation tissue towards fibrotic scar formation [29]. Myxoid areas in pleomorphic adenoma of the salivary gland and odontogenic myxoma lack expression of biglycan, lumican, and decorin, whereas these SLRPs are diffusely present in the fibrotic parts of the ECM of these tumors (Table 2). This suggests that the absence of SLRPs might contribute to impaired ECM formation resulting in a mere myxoid morphology.

Collagens

As form follows function [30], different collagens have different properties. In the initial phase of wound healing, collagen type I is quickly produced by fibroblasts and replaced by collagen type III in the later stage of scar formation [29]. The FACIT collagen types XII and XIV do not form collagen fibrils themselves but associate with fibrillary collagens, such as collagen type I, decorin, and GAGs, linking them together [31, 32, 33]. Collagen type XIV interacts with dermatan sulfate sequences on the single chondroitin sulfate/dermatan sulfate chain attached to decorin, thereby providing a link between the fibril-forming and the fibril-associated collagens [32]. Collagen type XIV is expressed significantly higher in grade I myxofibrosarcoma than in intramuscular myxoma (including its cellular variant) [34]. On one hand, this might have implications for ECM assembly and tumor development, thereby playing a potential role in the different biology and clinical behavior of these different entities; on the other hand, the effect of cell–ECM interaction in these tumors might work the other way around, as collagen XIV induces differentiation of fibroblastic cells [35]. Higher expression of collagen XIV in myxofibrosarcoma is associated with a more mature morphology of the tumor cells compared to intramuscular myxoma [5].

Other ECM molecules

Fibronectin plays a role in various biological processes, such as wound healing, host defense, regulation of ECM assembly, adhesion, and proliferation [36]. It is also a key molecule in cell–ECM signaling, and aberrant activation of fibronectin–ECM signaling has been described in many tumors [37]. Likewise, tenascin C is an ECM glycoprotein of which the spatial and temporal expression is tightly regulated during fetal development [38]. It has been shown that the tenascin C-encoding gene is upregulated in several pathologic conditions, such as wound healing, inflammation, and malignancies [38]. Elevated tenascin C expression has been found in epithelial and mesenchymal tumors, both in tumor and stromal cells, and is associated with unfavorable disease outcome (Table 2) [18]. Tenascin C attaches to cells via integrins, though the effect of this interaction on cellular signaling and tumor development is largely unknown [39].

Putative relevance for routine pathology practice

In routine general practice, one encounters a group of tumors, mesenchymal as well as epithelial, which may show variable degrees of myxoid appearance of their ECM. Myxoid tumors of soft tissue, the focus of this paper, encompass a heterogeneous group of lesions characterized by a marked abundance of extracellular mucoid/myxoid matrix (Table 1). This group of tumors exhibits a broad range of biological behavior varying from those which are entirely benign via locally aggressive (but nonmetastasizing) behavior to those which are frankly malignant; hence, accurate histopathological diagnosis is essential for appropriate clinical management. Till today, there have been no convincing data which demonstrate that the composition of the myxoid matrix significantly differ between tumors (both of mesenchymal and/or epithelial origin) and reactive lesions. From a biochemical point of view, the term “myxoid” is best considered a wastebasket of many different proteins and other (macro)molecules which might all have a different function (Tables 2 and 3). While determination of the different GAGs in myxoid tumors is interesting from a research point of view, Scott’s critical electrolyte concentration (CEC) method is no longer a routinely used technique by pathologists. Most myxoid tumors of soft tissue tumors contain HA (Table 2), and consequently, its detection is no longer regarded as discriminatory in differential diagnoses. Outside the academic setting (where recourse to sophisticated biochemical and molecular genetics techniques is generally not possible), when confronted with challenging myxoid lesions, the diagnostic process relies primarily on careful and discriminatory histopathological evaluation in order to reach a correct diagnosis. Routine histological criteria (e.g., tumor demarcation, growth and vascular pattern, and nuclear atypia) remain the hallmarks of diagnosis. (Immuno-)histochemistry may be useful as a adjunct in the setting of certain differential diagnostic considerations, but is often not discriminatory and, therefore, not diagnostically useful [8]. Molecular cytogenetics is of increasing importance for diagnosis in difficult cases, as the genetic makeup of an increasing number of myxoid tumors of soft tissue is being elucidated (Table 1). Next to genetic causes (such as driver mutations, translocations, or gene amplifications), environmental factors have been shown to play an important role in tumorigenesis of both epithelial and mesenchymal tumors [40]. Virchow already mentioned the possible relationship between the histological appearance of the myxoid ECM of tumors and their differences in biological behavior [1]. It is very tempting to believe that GAGs and PGs play an important role in the biology of myxoid lesions rather than just being a byproduct of (myo)fibroblastic differentiation. Intramuscular myxoma expresses significantly less decorin and collagen VI and XIV (both protein and mRNA level) than grade I myxofibrosarcoma [34]. Next to decorin, liquid chromatography–mass spectrometry revealed other SLRPs (i.e., lumican, prolargin 4, biglycan) present in tumor lysates of grade I myxofibrosarcoma but not of intramuscular myxoma [34]. This suggest that ECM formation in intramuscular myxoma is impaired compared to grade I myxofibrosarcoma. Increased ECM rigidity activates integrins and subsequently leads to stimulation of the rho/Rock pathway and cell migration and invasion [41]. In this respect, the morphological similarity between the process of wound healing and myxoid changes/areas in (non)neoplastic lesions is rather striking. In the early phase, granulation tissue shows a loose, edematous/myxoid ECM rich in GAGs. In the subsequent phase, there is structural organization of the ECM with deposition of collagens produced by myofibroblasts which locally (de)differentiate from fibroblast/smooth muscle cells or are derived from the bone marrow. The term “myxoid” might not only be synonymous with (aberrant turnover and) the presence of GAGs, but also reflects the absence of proper ECM assembly or incomplete ECM formation. This might well explain that a myxoid morphology of the ECM is not specific at all and can be seen in reactive/non-neoplastic processes as well as in benign and malignant tumors (Fig. 3). As already extensively discussed in this paper, the ECM is dependent on the interplay of various macromolecules (polysaccharides and proteins) which determine its texture and consistency. It is becoming increasingly clear that, within this group of lesions, various tumor types may show differences in the biological composition of their myxoid matrix, as determined by differences in the relative proportions of the constituent macromolecules and the presence or absence of specific stromal constituents. Clearly, this is an important and highly relevant area for further research in order to identify tumor-specific markers and to consequently develop economically viable and user-friendly detection methods to facilitate the diagnostic process and ensure increasingly accurate histopathologic diagnosis.

Notes

Acknowledgements

Stefan M. Willems was financially supported by a grant from The Netherlands Organization for Health Research and Development (project no. 920-03-403).

Conflict of interest statement

We declare that we have no conflict of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

  1. 1.
    Virchow R (1858) Die cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre. Hirschwald, BerlinGoogle Scholar
  2. 2.
    Dunglison R (1865) Medical lexicon. A dictionary of medical science. Blanchard and Lea, PhiladelphiaGoogle Scholar
  3. 3.
    Muller J (1838) Uber den feineren bau und die formen der krankhaften geschwulste. Haberling, BerlinGoogle Scholar
  4. 4.
    Bryant T (1802) Tumors and tumor formation. Churchill, New York.Google Scholar
  5. 5.
    Stout AP (1948) Myxoma, the tumor of primitive mesenchyme. Ann Surg 127:706–719CrossRefPubMedGoogle Scholar
  6. 6.
    Sponsel KH, McDonald JR, Ghormley RK (1952) Myxoma and myxosarcoma of the soft tissues of the extremities. J Bone Joint Surg Am 34(A):820–826PubMedGoogle Scholar
  7. 7.
    Fletcher CDM, Unni KK, Mertens F (2002) WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC, LyonGoogle Scholar
  8. 8.
    Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM (1999) Myxoid tumours of soft tissue. Histopathology 35:291–312CrossRefPubMedGoogle Scholar
  9. 9.
    Steedman HF (1950) Alcian Blue 8 GS: a new stain for mucin. Q J Microsc Sci 3:477–479Google Scholar
  10. 10.
    Scott JE, Dorling J (1965) Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions. Histochemie 5:221–233CrossRefPubMedGoogle Scholar
  11. 11.
    Kindblom LG, Angervall L (1975) Histochemical characterization of mucosubstances in bone and soft tissue-tumors. Cancer 36:985–994CrossRefPubMedGoogle Scholar
  12. 12.
    Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455–482CrossRefPubMedGoogle Scholar
  13. 13.
    Kresse H, Schonherr E (2001) Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189:266–274CrossRefPubMedGoogle Scholar
  14. 14.
    Schaefer L, Iozzo RV (2008) Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283:21305–21309CrossRefPubMedGoogle Scholar
  15. 15.
    Kadler KE, Hill A, Canty-Laird EG (2008) Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 20:495–501CrossRefPubMedGoogle Scholar
  16. 16.
    White ES, Baralle FE, Muro AF (2008) New insights into form and function of fibronectin splice variants. J Pathol 216:1–14CrossRefPubMedGoogle Scholar
  17. 17.
    Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200:423–428CrossRefPubMedGoogle Scholar
  18. 18.
    Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163CrossRefPubMedGoogle Scholar
  19. 19.
    Lamoureux F, Baud’huin M, Duplomb L et al (2007) Proteoglycans: key partners in bone cell biology. BioEssays 29:758–771CrossRefPubMedGoogle Scholar
  20. 20.
    Willems SM, Schrage YM, Baelde JJ et al (2008) Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 52:465–474CrossRefPubMedGoogle Scholar
  21. 21.
    Almond A (2007) Hyaluronan. Cell Mol Life Sci 64:1591–1596CrossRefPubMedGoogle Scholar
  22. 22.
    Rodgers KD, San Antonio JD, Jacenko O (2008) Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators. Dev Dyn 237:2622–2642CrossRefPubMedGoogle Scholar
  23. 23.
    Evanko SP, Angello JC, Wight TN (1999) Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:1004–1013PubMedGoogle Scholar
  24. 24.
    Zimmermann DR, Dours-Zimmermann MT, Schubert M et al (1994) Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 124:817–825CrossRefPubMedGoogle Scholar
  25. 25.
    McEwan PA, Scott PG, Bishop PN et al (2006) Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol 155:294–305CrossRefPubMedGoogle Scholar
  26. 26.
    Geng Y, McQuillan D, Roughley PJ (2006) SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 25:484–491CrossRefPubMedGoogle Scholar
  27. 27.
    Ferdous Z, Wei VM, Iozzo R et al (2007) Decorin-transforming growth factor- interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 282:35887–35898CrossRefPubMedGoogle Scholar
  28. 28.
    Danielson KG, Baribault H, Holmes DF et al (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136:729–743CrossRefPubMedGoogle Scholar
  29. 29.
    Martinez DA, Vailas AC, Vanderby R et al (2007) Temporal extracellular matrix adaptations in ligament during wound healing and hindlimb unloading. Am J Physiol Regul Integr Comp Physiol 293:R1552–R1560PubMedGoogle Scholar
  30. 30.
    Sullivan LH (1896) The tall office building artistically considered. Lippincott’s Magazine 57:403–409Google Scholar
  31. 31.
    Ehnis T, Dieterich W, Bauer M et al (1997) Localization of a binding site for the proteoglycan decorin on collagen XIV (undulin). J Biol Chem 272:20414–20419CrossRefPubMedGoogle Scholar
  32. 32.
    Ehnis T, Dieterich W, Bauer M et al (1996) A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Exp Cell Res 229:388–397CrossRefPubMedGoogle Scholar
  33. 33.
    Canty EG, Kadler KE (2005) Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 118:1341–1353CrossRefPubMedGoogle Scholar
  34. 34.
    Willems SM, Mohseny AB, Balog C et al (2009) Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 7:1291–1301CrossRefGoogle Scholar
  35. 35.
    Ruehl M, Erben U, Schuppan D et al (2005) The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes. J Biol Chem 280:38537–38543CrossRefPubMedGoogle Scholar
  36. 36.
    Vakonakis I, Campbell ID (2007) Extracellular matrix: from atomic resolution to ultrastructure. Curr Opin Cell Biol 19:578–583CrossRefPubMedGoogle Scholar
  37. 37.
    Larsen M, Artym VV, Green JA et al (2006) The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18:463–471CrossRefPubMedGoogle Scholar
  38. 38.
    Harty M, Neff AW, King MW et al (2003) Regeneration or scarring: an immunologic perspective. Dev Dyn 226:268–279CrossRefPubMedGoogle Scholar
  39. 39.
    Jones FS, Jones PL (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218:235–259CrossRefPubMedGoogle Scholar
  40. 40.
    De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447CrossRefPubMedGoogle Scholar
  41. 41.
    Berrier AL, Yamada KM (2007) Cell–matrix adhesion. J Cell Physiol 213:565–573CrossRefPubMedGoogle Scholar
  42. 42.
    Fletcher CDM (1990) Benign fibrous histiocytoma of subcutaneous and deep soft tissue: a clinicopathologic analysis of 21 cases. Am J Surg Pathol 14:801–809PubMedGoogle Scholar
  43. 43.
    Carney JA, Gordon H, Carpenter PC et al (1985) The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64:270–283Google Scholar
  44. 44.
    Meng GZ, Zhang HY, Zhang Z et al (2009) Myofibroblastic sarcoma vs nodular fasciitis: a comparative study of chromosomal imbalances. Am J Clin Pathol 131:701–709CrossRefPubMedGoogle Scholar
  45. 45.
    Perdigao PF, Stergiopoulos SG, De Marco L et al (2005) Molecular and immunohistochemical investigation of protein kinase a regulatory subunit type 1A (PRKAR1A) in odontogenic myxomas. Genes Chromosomes Cancer 44:204–211CrossRefPubMedGoogle Scholar
  46. 46.
    Hallor KH, Sciot R, Staaf J et al (2009) Two genetic pathways, t(1;10) and amplification of 3p11–12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 217:716–727CrossRefPubMedGoogle Scholar
  47. 47.
    Calonje E, Mentzel T, Fletcher CDM (1994) Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am J Surg Pathol 18:668–676PubMedCrossRefGoogle Scholar
  48. 48.
    Willems SM, Debiec-Rychter M, Szuhai K et al (2006) Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 19:407–416CrossRefPubMedGoogle Scholar
  49. 49.
    Enzinger FM, Shiraki M (1972) Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol 3:421–435CrossRefPubMedGoogle Scholar
  50. 50.
    Evans HL (1993) Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol 17:595–600CrossRefPubMedGoogle Scholar
  51. 51.
    Turc-Carel C, Limon J, Dal CP et al (1986) Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 23:291–299CrossRefPubMedGoogle Scholar
  52. 52.
    Rubin BP, Fletcher CDM (2000) Myxoid leiomyosarcoma of soft tissue, an underrecognized variant. Am J Surg Pathol 24:927–936CrossRefPubMedGoogle Scholar
  53. 53.
    Brems H, Beert E, De Ravel RT et al (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508–515CrossRefPubMedGoogle Scholar
  54. 54.
    Pedeutour F, Simon MP, Minoletti F et al (1996) Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 72:171–174CrossRefPubMedGoogle Scholar
  55. 55.
    Kaya G, Augsburger E, Chavaz P et al (2006) CD44 and hyaluronate expression in follicular mucinosis. J Cutan Pathol 33:227–230CrossRefPubMedGoogle Scholar
  56. 56.
    Alves MF, Filgueira AL, Lorena DE et al (1998) Type I and type III collagens in cutaneous mucinosis. Am J Dermatopathol 20:41–47CrossRefPubMedGoogle Scholar
  57. 57.
    Lengyel J, Vertes B (1956) Hyaluronic acid studies of local myxedema and of the stroma of skin cancer. Dermatologica 113:219–225CrossRefPubMedGoogle Scholar
  58. 58.
    Chung IM, Gold HK, Schwartz SM et al (2002) Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 40:2072–2081CrossRefPubMedGoogle Scholar
  59. 59.
    Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14:617–623CrossRefPubMedGoogle Scholar
  60. 60.
    Burke AP, Jarvelainen H, Kolodgie FD et al (2004) Superficial pseudoaneurysms: clinicopathologic aspects and involvement of extracellular matrix proteoglycans. Mod Pathol 17:482–488CrossRefPubMedGoogle Scholar
  61. 61.
    Black A, French AT, Dukes-McEwan J et al (2005) Ultrastructural morphologic evaluation of the phenotype of valvular interstitial cells in dogs with myxomatous degeneration of the mitral valve. Am J Vet Res 66:1408–1414CrossRefPubMedGoogle Scholar
  62. 62.
    Nasuti JF, Zhang PJ, Feldman MD et al (2004) Fibrillin and other matrix proteins in mitral valve prolapse syndrome. Ann Thorac Surg 77:532–536CrossRefPubMedGoogle Scholar
  63. 63.
    Aigner T, Oliveira AM, Nascimento AG (2004) Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotype. Mod Pathol 17:214–221CrossRefPubMedGoogle Scholar
  64. 64.
    Zhao M, Lu Y, Takata T, Mock D, Nikia H et al (1999) Immunohistochemical and histochemical characterization of the mucosubstances of odontogenic myxoma: histogenesis and differential diagnosis. Pathol Res Pract 195:391–397PubMedGoogle Scholar
  65. 65.
    Zamecnik M, Michal M (2000) Low-grade fibromyxoid sarcoma: a report of eight cases with histologic, immunohistochemical, and ultrastructural study. Ann Diagn Pathol 4:207–217CrossRefPubMedGoogle Scholar
  66. 66.
    Gallager RL, Helwig EB (1980) Neurothekeoma—a benign cutaneous tumor of neural origin. Am J Clin Pathol 74:759–764PubMedGoogle Scholar
  67. 67.
    Hajdu SI (1979) Pathology of soft tissue Tumors. Lea and Febiger, PhiladelphiaGoogle Scholar
  68. 68.
    Fukuda T, Tsuneyoshi M (2000) Adhesion proteins, cellular morphology and fibrous components around the cell/extracellular-matrix interface in myxoid liposarcomas. J Cancer Res Clin Oncol 126:320–324CrossRefPubMedGoogle Scholar
  69. 69.
    Mackenzie DH (1981) The myxoid tumors of somatic soft tissues. Am J Surg Pathol 5:443–458PubMedCrossRefGoogle Scholar
  70. 70.
    Soder S, Inwards C, Muller S et al (2001) Cell biology and matrix biochemistry of chondromyxoid fibroma. Am J Clin Pathol 116:271–277CrossRefPubMedGoogle Scholar
  71. 71.
    Calikoglu E, Chavaz P, Saurat JH et al (2003) Decreased CD44 expression and stromal hyaluronate accumulation in myxoid dermatofibroma. Dermatology 207:104–106CrossRefPubMedGoogle Scholar
  72. 72.
    Yasui W, Oda N, Ito H et al (1991) Myxoid leiomyosarcoma of the stomach: a case report. Jpn J Clin Oncol 21:447–452PubMedGoogle Scholar
  73. 73.
    Lam RM, Hawkins ET, Roszka J (1984) Cardiac myxoma: histochemical and ultrastructural localization of glycosaminoglycans and proteoglycans. Ultrastruct Pathol 6:69–81CrossRefPubMedGoogle Scholar
  74. 74.
    Folpe AL, Weiss SW (2003) Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol 27:421–431CrossRefPubMedGoogle Scholar
  75. 75.
    Yang P, Hirose T, Hasegawa T et al (1994) Ossifying fibromyxoid tumor of soft parts: a morphological and immunohistochemical study. Pathol Int 44:448–453CrossRefPubMedGoogle Scholar
  76. 76.
    Hassanein AM, Atkinson SP, Al-Quran SZ et al (2008) Acral myxoinflammatory fibroblastic sarcomas: are they all low-grade neoplasms? J Cutan Pathol 35:186–191PubMedGoogle Scholar
  77. 77.
    Johnson WC, Graham JH, Helwig EB (1965) Cutaneous myxoid cyst. A clinicopathological and histochemical study. JAMA 191:15–20PubMedGoogle Scholar
  78. 78.
    Begin LR, Clement PB, Kirk ME et al (1985) Aggressive angiomyxoma of pelvic soft parts: a clinicopathologic study of nine cases. Hum Pathol 16:621–628CrossRefPubMedGoogle Scholar
  79. 79.
    Calikoglu E, Augsburger E, Masouye I et al (2002) Hyaluronate accumulation and decreased CD44 expression in perifollicular solitary cutaneous myxoma. Dermatology 205:122–126CrossRefPubMedGoogle Scholar
  80. 80.
    Kusafuka K, Muramatsu K, Kasami M et al (2008) Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules. Mod Pathol 21:1282–1292CrossRefPubMedGoogle Scholar
  81. 81.
    Kusafuka K, Ishiwata T, Sugisaki Y et al (2004) Lumican expression is associated with the formation of mesenchyme-like elements in salivary pleomorphic adenomas. J Pathol 203:953–960CrossRefPubMedGoogle Scholar
  82. 82.
    Nara Y, Takeuchi J, Yoshida K et al (1991) Immunohistochemical characterisation of extracellular matrix components of salivary gland tumours. Br J Cancer 64:307–314PubMedGoogle Scholar
  83. 83.
    Kusafuka K, Hiraki Y, Shukunami C et al (2001) Cartilage-specific matrix protein chondromodulin-I is associated with chondroid formation in salivary pleomorphic adenomas: immunohistochemical analysis. Am J Pathol 158:1465–1472PubMedGoogle Scholar
  84. 84.
    Ambros RA, Kallakury BV, Malfetano JH et al (1996) Cytokine, cell adhesion receptor, and tumor suppressor gene expression in vulvar squamous carcinoma: correlation with prominent fibromyxoid stromal response. Int J Gynecol Pathol 15:320–325PubMedGoogle Scholar
  85. 85.
    Franchi A, Dini M, Paglierani M et al (1995) Immunolocalization of extracellular matrix components in mixed tumors of the skin. Am J Dermatopathol 17:36–41PubMedGoogle Scholar
  86. 86.
    Sabit H, Tsuneyama K, Shimonishi T et al (2001) Enhanced expression of basement-membrane-type heparan sulfate proteoglycan in tumor fibro-myxoid stroma of intrahepatic cholangiocarcinoma. Pathol Int 51:248–256CrossRefPubMedGoogle Scholar
  87. 87.
    Giordana MT, Bertolotto A, Mauro A et al (1982) Glycosaminoglycans in human cerebral tumors. Part II. Histochemical findings and correlations. Acta Neuropathol 57:299–305CrossRefPubMedGoogle Scholar
  88. 88.
    Shia J, Qin J, Erlandson RA et al (2005) Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. Virchows Arch 447:828–834CrossRefPubMedGoogle Scholar
  89. 89.
    Harrison JD, Rose PE (1985) Myxoid meningioma: histochemistry and electron microscopy. Acta Neuropathol 68:80–82CrossRefPubMedGoogle Scholar
  90. 90.
    Henschen F (1926) Fall von ostitis Fibrosa mit multiplen Tumoren in deer umgebenden Muskulatur. Verh Dtsch Ges Pathol 21:93–97Google Scholar
  91. 91.
    Mazabraud A, Semat P, Roze R (1967) A propos de l’association de fibromyxomes des tissus mous à la dysplasie fibreuse des os. Presse Med 75:2223–2228PubMedGoogle Scholar
  92. 92.
    Weiss SW, Enzinger FM (1977) Myxoid variant of malignant fibrous histiocytoma. Cancer 39:1672–1685CrossRefPubMedGoogle Scholar
  93. 93.
    Angervall L, Kindblom LG, Merck C (1977) Myxofibrosarcoma. A study of 30 cases. Acta Pathol Microbiol Scand A 85A:127–140PubMedGoogle Scholar
  94. 94.
    Orndal C, Mandahl N, Rydholm A et al (1990) Chromosomal evolution and tumor progression in a myxoid liposarcoma. Acta Orthop Scand 61:99–105PubMedCrossRefGoogle Scholar
  95. 95.
    Mentzel T, Calonje E, Wadden C et al (1996) Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20:391–405CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2009

Authors and Affiliations

  • Stefan M. Willems
    • 1
  • Malgorzata Wiweger
    • 1
  • J. Frans Graadt van Roggen
    • 2
  • Pancras C. W. Hogendoorn
    • 1
  1. 1.Department of PathologyLeiden University Medical CenterLeidenThe Netherlands
  2. 2.Department of PathologyDiaconessenhuis HospitalLeidenThe Netherlands

Personalised recommendations